Advances in peptide drug development and the rising prevalence of hematological disorders are driving demand for peptide-based therapeu ...

Arexvy is an RSV vaccine currently authorised in the US and a further 35 countries. Credit: MargJohnsonVA/Shutterstock. GlaxoSmithKline (GSK) has received approval ...

The GSK (LSE:GSK) share price has fallen off its perch. So it may be a good time to research and consider the stock opportunity. I think the global biopharma company has been dripping with promise ...

The GSK share price has tumbled recently on a number of factors, but I think its fundamentals look strong, leaving the stock undervalued right now. When investing, your capital is at risk.

A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, positioning both companies to compete for that market and laying down a marker for ...

GSK’s (LSE: GSK) share price is down 28% from its 15 May 12-month traded high of £18.19. As a shareholder, this raises the question of whether I should sell, keep what I have, or buy more. In my ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to launch the first treatment for the relentless itching experienced by some ...

Nov 19 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called ...

GSK stock remains in a deep bear market, falling by 27% from the year-to-date high. The company made strong progress on its linerixibat trial. There are concerns about Robert Kennedy Jr ...